Compare Stocks: DCTH, ESTA, NVCR, and LMAT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCTH Delcath Systems	$16.39 -0.1%	$13.94	$8.12 ▼ $17.42	$569.06M	0.52	744,608 shs	402,571 shs
ESTA Establishment Labs	$71.80 -0.9%	$85.28	$36.53 ▼ $97.59	$2.16B	1.07	541,777 shs	229,749 shs
LMAT LeMaitre Vascular	$79.67 +0.1%	$93.31	$78.27 ▼ $118.01	$1.82B	0.53	461,541 shs	208,751 shs
NVCR NovoCure	$17.99 +0.6%	$16.45	$9.82 ▼ $21.45	$2.08B	0.97	1.35 million shs	762,935 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCTH Delcath Systems	-3.07%	-4.37%	+37.35%	+49.77%	+47.48%
ESTA Establishment Labs	+0.42%	-3.86%	-21.34%	-0.73%	+73.49%
LMAT LeMaitre Vascular	+0.81%	-5.08%	-19.53%	-15.79%	-16.45%
NVCR NovoCure	+1.53%	-1.70%	+5.05%	+3.71%	+51.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCTH Delcath Systems	$16.39 -0.1%	$13.94	$8.12 ▼ $17.42	$569.06M	0.52	744,608 shs	402,571 shs
ESTA Establishment Labs	$71.80 -0.9%	$85.28	$36.53 ▼ $97.59	$2.16B	1.07	541,777 shs	229,749 shs
LMAT LeMaitre Vascular	$79.67 +0.1%	$93.31	$78.27 ▼ $118.01	$1.82B	0.53	461,541 shs	208,751 shs
NVCR NovoCure	$17.99 +0.6%	$16.45	$9.82 ▼ $21.45	$2.08B	0.97	1.35 million shs	762,935 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCTH Delcath Systems	-3.07%	-4.37%	+37.35%	+49.77%	+47.48%
ESTA Establishment Labs	+0.42%	-3.86%	-21.34%	-0.73%	+73.49%
LMAT LeMaitre Vascular	+0.81%	-5.08%	-19.53%	-15.79%	-16.45%
NVCR NovoCure	+1.53%	-1.70%	+5.05%	+3.71%	+51.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DCTH Delcath Systems	2.86	Moderate Buy	$23.17	41.35% Upside
ESTA Establishment Labs	2.78	Moderate Buy	$100.25	39.62% Upside
LMAT LeMaitre Vascular	2.33	Hold	$110.60	38.82% Upside
NVCR NovoCure	2.14	Hold	$21.20	17.84% Upside

Current Analyst Ratings Breakdown

Latest DCTH, ESTA, NVCR, and LMAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	DCTH Delcath Systems	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/14/2026	LMAT LeMaitre Vascular	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/13/2026	ESTA Establishment Labs	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$92.00
8/10/2026	DCTH Delcath Systems	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	DCTH Delcath Systems	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/7/2026	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00 ➝ $32.00
8/7/2026	ESTA Establishment Labs	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$84.00 ➝ $95.00
8/6/2026	ESTA Establishment Labs	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$105.00
8/6/2026	DCTH Delcath Systems	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $21.00
8/6/2026	ESTA Establishment Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $103.00
8/6/2026	ESTA Establishment Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$86.00 ➝ $95.00

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DCTH Delcath Systems	$85.23M	6.67	$0.05 per share	313.73	$3.49 per share	4.70
ESTA Establishment Labs	$211.08M	10.14	N/A	N/A	$0.73 per share	98.36
LMAT LeMaitre Vascular	$249.60M	7.30	$2.90 per share	27.43	$18.38 per share	4.33
NVCR NovoCure	$655.35M	3.20	N/A	N/A	$2.90 per share	6.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DCTH Delcath Systems	$2.70M	$0.01	1,640.64	136.58	N/A	0.56%	0.46%	0.42%	11/3/2026 (Estimated)
ESTA Establishment Labs	-$51.06M	-$1.31	N/A	7,180.00	N/A	-15.82%	-196.69%	-10.73%	11/4/2026 (Estimated)
LMAT LeMaitre Vascular	$57.73M	$2.85	27.95	25.13	2.30	25.02%	15.63%	10.06%	11/5/2026 (Estimated)
NVCR NovoCure	-$136.23M	-$1.30	N/A	N/A	N/A	-21.25%	-44.00%	-15.85%	10/29/2026 (Estimated)

Latest DCTH, ESTA, NVCR, and LMAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	DCTH Delcath Systems	-$0.0891	$0.07	+$0.1591	$0.07	$26.25 million	$29.13 million
8/6/2026	Q2 2026	ESTA Establishment Labs	-$0.3368	-$0.39	-$0.0532	-$0.39	$65.79 million	$67.54 million
8/4/2026	Q2 2026	LMAT LeMaitre Vascular	$0.8070	$0.74	-$0.0670	$0.74	$71.47 million	$70.38 million
7/23/2026	Q2 2026	NVCR NovoCure	-$0.3315	-$0.13	+$0.2015	-$0.13	$172.44 million	$183.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
ESTA Establishment Labs	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$1.00	1.26%	+16.05%	35.09%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A

Latest DCTH, ESTA, NVCR, and LMAT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	LMAT LeMaitre Vascular	quarterly	$0.25	1.21%	8/20/2026	8/20/2026	9/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DCTH Delcath Systems	N/A	9.83	8.95
ESTA Establishment Labs	12.11	3.84	2.52
LMAT LeMaitre Vascular	0.40	16.31	13.96
NVCR NovoCure	0.58	2.89	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DCTH Delcath Systems	61.12%
ESTA Establishment Labs	72.91%
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%

Insider Ownership

Company	Insider Ownership
DCTH Delcath Systems	19.36%
ESTA Establishment Labs	9.99%
LMAT LeMaitre Vascular	7.40%
NVCR NovoCure	6.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DCTH Delcath Systems	60	34.70 million	27.98 million	Optionable
ESTA Establishment Labs	1,004	29.80 million	26.83 million	Optionable
LMAT LeMaitre Vascular	490	22.87 million	21.18 million	Optionable
NVCR NovoCure	1,605	116.45 million	108.82 million	Optionable

DCTH, ESTA, NVCR, and LMAT Headlines

Recent News About These Companies

NovoCure (NASDAQ:NVCR) Shares Down 4% - What's Next?

August 21, 2026 | marketbeat.com

Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice

August 20, 2026 | zacks.com

Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet

August 12, 2026 | zacks.com

Sei Investments Co. Buys 89,839 Shares of NovoCure Limited $NVCR

August 12, 2026 | marketbeat.com

First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR

August 11, 2026 | marketbeat.com

Dimensional Fund Advisors LP Buys 207,913 Shares of NovoCure Limited $NVCR

August 10, 2026 | marketbeat.com

NovoCure (NASDAQ:NVCR) Rating Increased to Buy at Wall Street Zen

August 8, 2026 | marketbeat.com

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

August 7, 2026 | zacks.com

NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Hold" from Brokerages

August 3, 2026 | marketbeat.com

Quantinno Capital Management LP Has $27.11 Million Stock Position in NovoCure Limited $NVCR

August 1, 2026 | marketbeat.com

NovoCure Limited $NVCR Shares Bought by Renaissance Technologies LLC

July 31, 2026 | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Sells 201,000 Shares of NovoCure Limited $NVCR

July 29, 2026 | marketbeat.com

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?

July 27, 2026 | zacks.com

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade

July 27, 2026 | zacks.com

Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects

July 27, 2026 | zacks.com

NovoCure's strongest quarter ever isn't enough to stop NVCR stock from sliding

July 25, 2026 | msn.com

NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds

July 25, 2026 | finance.yahoo.com

NovoCure: Why I'm Fading The Q2 Earnings Rally

July 24, 2026 | seekingalpha.com

NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)

July 24, 2026 | seekingalpha.com

NovoCure Limited 2026 Q2 - Results - Earnings Call Presentation

July 24, 2026 | seekingalpha.com

Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes

July 23, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DCTH, ESTA, NVCR, and LMAT Company Descriptions

Delcath Systems NASDAQ:DCTH

$16.39 -0.01 (-0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$16.39 0.00 (-0.03%)

As of 07:30 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Establishment Labs NASDAQ:ESTA

$71.80 -0.65 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$71.82 +0.03 (+0.03%)

As of 07:30 PM Eastern

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

LeMaitre Vascular NASDAQ:LMAT

$79.67 +0.06 (+0.08%)

Closing price 04:00 PM Eastern

Extended Trading

$79.72 +0.05 (+0.06%)

As of 07:56 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$17.99 +0.10 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$17.70 -0.29 (-1.61%)

As of 07:30 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DCTH, ESTA, NVCR, and LMAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DCTH, ESTA, NVCR, and LMAT Earnings

Compare Dividends

Latest DCTH, ESTA, NVCR, and LMAT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DCTH, ESTA, NVCR, and LMAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DCTH, ESTA, NVCR, and LMAT Company Descriptions

Delcath Systems NASDAQ:DCTH

Establishment Labs NASDAQ:ESTA

LeMaitre Vascular NASDAQ:LMAT

NovoCure NASDAQ:NVCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools